title: MEDI4893* Promotes Survival and Extends the Antibiotic Treatment Window in a Staphylococcus aureus Immunocompromised Pneumonia Model.
abstract: Immunocompromised individuals are at increased risk of Staphylococcus aureus pneumonia. Neutralization of alpha-toxin (AT) with the monoclonal antibody (MAb) MEDI4893* protects normal mice from S. aureus pneumonia; however, the effects of the MAb in immunocompromised mice have not been reported. In this study, passive immunization with MEDI4893* increased survival rates and reduced bacterial numbers in the lungs in an immunocompromised murine S. aureus pneumonia model. Lungs from infected mice exhibited alveolar epithelial damage, protein leakage, and bacterial overgrowth, whereas lungs from mice passively immunized with MEDI4893* retained a healthy architecture, with an intact epithelial barrier. Adjunctive therapy or prophylaxis with a subtherapeutic MEDI4893* dose combined with subtherapeutic doses of vancomycin or linezolid improved survival rates, compared with the monotherapies. Furthermore, coadministration of MEDI4893* with vancomycin or linezolid extended the antibiotic treatment window. These data suggest that MAb-mediated neutralization of AT holds promise in strategies for prevention and adjunctive therapy among immunocompromised patients.
authors.affiliation: Department of Infectious Disease, MedImmune, LLC, Gaithersburg, Maryland, USA.
authors.forename: L
authors.initials: L
authors.lastname: Hua
authors.affiliation: Department of Infectious Disease, MedImmune, LLC, Gaithersburg, Maryland, USA.
authors.forename: T S
authors.initials: TS
authors.lastname: Cohen
authors.affiliation: Department of Infectious Disease, MedImmune, LLC, Gaithersburg, Maryland, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Shi
authors.affiliation: Department of Translational Science, MedImmune, LLC, Gaithersburg, Maryland, USA.
authors.forename: V
authors.initials: V
authors.lastname: Datta
authors.affiliation: Department of Infectious Disease, MedImmune, LLC, Gaithersburg, Maryland, USA.
authors.forename: J J
authors.initials: JJ
authors.lastname: Hilliard
authors.affiliation: Department of Infectious Disease, MedImmune, LLC, Gaithersburg, Maryland, USA.
authors.forename: C
authors.initials: C
authors.lastname: Tkaczyk
authors.affiliation: Department of Infectious Disease, MedImmune, LLC, Gaithersburg, Maryland, USA.
authors.forename: J
authors.initials: J
authors.lastname: Suzich
authors.affiliation: Department of Infectious Disease, MedImmune, LLC, Gaithersburg, Maryland, USA.
authors.forename: C K
authors.initials: CK
authors.lastname: Stover
authors.affiliation: Department of Infectious Disease, MedImmune, LLC, Gaithersburg, Maryland, USA sellmanb@medimmune.com.
authors.forename: B R
authors.initials: BR
authors.lastname: Sellman
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing / Q000494:pharmacology*; D000080908:Broadly Neutralizing Antibodies; D005260:Female; D016867:Immunocompromised Host / Q000187:drug effects*; D000069349:Linezolid / Q000494:pharmacology; D008168:Lung / Q000382:microbiology; D051379:Mice; D008810:Mice, Inbred C57BL; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy*; D013211:Staphylococcus aureus / Q000187:drug effects*; D015996:Survival Rate; D014640:Vancomycin / Q000494:pharmacology
chemical_list: D000900:Anti-Bacterial Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D057134:Antibodies, Neutralizing; D000080908:Broadly Neutralizing Antibodies; C000600718:suvratoxumab; D014640:Vancomycin; D000069349:Linezolid